ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-TMPRSS6 Monoclonal Antibody DISC-3405

Also written as “DISC-3405” and “9MW3011”.

Its studies are mostly in Polycythemia Vera · Anemia, Sickle Cell · beta-Thalassemia, led by 2 companies.

Drug pageAnti-TMPRSS6 Monoclonal Antibody DISC-3405: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 2, since May 7, 20256 company-led studies, 4 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Disc Medicineits history only32 open or runningphase 2since May 7, 2025Sep 7, 2023Jun 2027phase 1 · NCT07187973
Mabwell (Shanghai) Bioscience32 open or runningphase 1since Feb 25, 2024Feb 25, 2024none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Mabwell (Shanghai) Bioscience only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 25, 2024First study: phase 1 study in HealthyFirst studyNCT06389942 · 48 enrolled · China
  2. Dec 23, 2024Phase 1 study in Polycythemia VeraNCT06752746 · 108 planned · China
  3. Jan 9, 2025Phase 1 study in beta-ThalassemiaNCT06772766 · 40 planned · China

TargetBeta

TMPRSS6 →read by rule
“A humanized monoclonal antibody directed against transmembrane serine protease 6 (TMPRSS6; matriptase-2), that can potentially be used to regulate TMPRSS6, hepcidin and iron levels and treat iron overload and anemia associated with certain disorders such as polycythemia vera (PV), beta thalassemia, ”NCIt, by rule

Other programs on TMPRSS6

ProgramCompanyFurthest phaseStudies
sapablursenruleIonis Pharmaceuticalsphase 34
AG-236ruleAgios Pharmaceuticalsphase 32

Studies

All 3 Mabwell (Shanghai) Bioscience leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06772766beta-Thalassemia · China1RecruitingOct 202640
NCT06752746Polycythemia Vera · China1RecruitingAug 31, 2025108
NCT06389942Healthy · China1CompletedMay 31, 202448

How it is read

Names in the registry

  • “DISC-3405”, 4 entries
  • “9MW3011”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.